Hims & Hers rises after FDA advisers endorse broader BPC-157 access - TipRanks
High confidence: full text extraction produced 1024 characters.
Shares of Hims & Hers are climbing after a Food and Drug Administration advisory panel voted Thursday to add the peptide BPC-157 to a list that would permit broader pharmacy compounding. The vote came in at eight in favor, six against, with one abstention. Hims & Hers stock is up roughly 10%, trading around $34.78.
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Published first on TheFly â the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers price target raised to $35 from $28 at Citi
- Cboe data shows mixed options sentiment in Hims and Hers Health with shares down 3.25%
- Hims & Hers app downloads reverse 10 month decline, says Morgan Stanley
- Hims & Hers Health Announces Accounting Officer Resignation
- Hims & Hers chief accounting officer Irene Becklund to depart